FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy

By E. Larkins, G. Blumenthal, Weishi Yuan, Kun He, R. Sridhara, Sriram Subramaniam, Hong Zhao, Chao Liu, Jingyu Yu, Kirsten B. Goldberg and 3 more. 2017

Subfields: Oncology, Otorhinolaryngology

Citations in the corpus

• Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “Additionally, a combination of Pembrolizumab with platinum and 5-fluorouracil (5-FU) chemotherapy can be chosen for treatment regardless of PD-L1 expression [9].”